Estrogen is thought to play a role in a woman’s risk of developing Alzheimer’s disease (AD), according to a new study
Alzheimer’s disease (AD) represents 60% to 70% of all dementia diagnoses and approximately two-thirds of those with AD are women.
A new study has examined the association between a woman’s reproductive life span as an indicator of endogenous estrogen exposure and levels of cerebrospinal fluid biomarkers.
During the study, a small sampling of women who were free of dementia and underwent natural menopause were followed for 25 years.
Cerebrospinal fluid samples
Based on the results from the cerebrospinal fluid samples, researchers concluded that a longer reproductive life was associated with increased levels of AD biomarkers in the preclinical phase of the disease.
“This small population-based study showed an association between duration of the reproductive life span (a surrogate marker for exposure to endogenous estrogen) and biomarkers of Alzheimer disease in the cerebrospinal fluid of women without dementia. This finding needs to be confirmed in larger studies but may be another factor contributing to the increased burden of Alzheimer disease in women that, at least in part, likely relates to ageing and the longer life expectancy in women compared with men,” says Dr Stephanie Faubion, NAMS medical director.
The study results have been published online in the article “Reproductive period and preclinical cerebrospinal fluid markers for Alzheimer disease: a 25-year study” in Menopause, the journal of The North American Menopause Society (NAMS).
I started out taking only Azilect, then Mirapex, and sinemet for my Parkinson disease, but as the disease progressed they didn’t help much. A year ago I started on PD TREATMENT PROTOCOL from Kykuyu Health Clinic (ww w. kykuyuhealthclinic. c om). One month into the treatment, I made a significant recovery. After I completed the recommended treatment, almost all my symptoms were gone. Its been months since I completed the treatment, I live a very product life